CRM197 is a genetically detoxified mutant of diphtheria toxin (DT) that is widely used as a carrier protein in conjugate vaccines. Protective immune responses to several bacterial diseases are obtained by…
Bio-Works Technologies launched an interview series called Water Cooler Chats, and the first guest interviewed (at BPI Boston) is none other than FinaBio's founder, Andrew Lees, Ph.D. https://www.youtube.com/watch?v=JMAZTD-B5Pk
Published in researchoutreach.org August 15, 2022 The immune system provides a formidable defence against pathogens. However, many bacteria possess a protective sugar polymer coat. In children, the immune system does…
FinaBio's CEO Andrew Lees was featured in this month's newsletter from the Maryland Tech Council promoting Maryland for the Life Sciences: It's Better in Maryland! Read the article here.
In this article in Vaccines I address how to control the chemistry and obtain reproducible results. Abstract CDAP (1-cyano-4-dimethylaminopyridine tetrafluoroborate) is employed in the synthesis of conjugate vaccines as a cyanylating…
For immediate release Fina Biosolutions founder Dr. Andrew Lees is the star of a video now playing on The Scientists’ Channel. In an exclusive interview, Lees, now the company’s CEO…
Johns Hopkins Medicine: Andrew Lees has worked his magic to make vaccines more effective. In 1984, Baltimore magazine was prescient when it put Andrew Lees, Ph.D. ’84, on the cover…
Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations Rockville, MD., November 4, 2020– Fina Biosolutions LLC (“FinaBio”) is very…
Rockville, Maryland’s Fina Biosolutions recently was awarded an SBIR grant to develop a genetically detoxified tetanus toxin as a carrier protein for conjugate vaccines. The NIAID funded grant is for $289,000 and…